High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury
Brain · 06.03.2025 · 148 (3) · 1015-1030
DOI: 10.1093/brain/awae305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 26.09.2024. Verfasst von Lucia M Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Sciences, Imperial College London, London W12 0BZ, UK. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Proteomics. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ERA-NET NEURON Cofund, The UK Dementia Research Institute, NIHR.
Abstract (Originalsprache)
Pathophysiology and outcomes after traumatic brain injury (TBI) are complex and heterogeneous. Current classifications are uninformative about pathophysiology. Proteomic approaches with fluid-based biomarkers are ideal for exploring complex disease mechanisms, because they enable sensitive assessment of an expansive range of processes potentially relevant to TBI pathophysiology. We used novel high-dimensional, multiplex proteomic assays to assess altered plasma protein expression in acute TBI. We analysed samples from 88 participants from the BIO-AX-TBI cohort [n = 38 moderate–severe TBI (Mayo Criteria), n = 22 non-TBI trauma and n = 28 non-injured controls] on two platforms: Alamar NULISA™ CNS Diseases and OLINK® Target 96 Inflammation. Patient participants were enrolled after hospital admission, and samples were taken at a single time point ≤10 days post-injury. Participants also had neurofilament light, GFAP, total tau, UCH-L1 (all Simoa®) and S100B (Millipore) data. The Alamar panel assesses 120 proteins, most of which were previously unexplored in TBI, plus proteins with known TBI specificity, such as GFAP. A subset (n = 29 TBI and n = 24 non-injured controls) also had subacute (10 days to 6 weeks post-injury) 3 T MRI measures of lesion volume and white matter injury (fractional anisotropy). Differential expression analysis identified 16 proteins with TBI-specific significantly different plasma expression. These were neuronal markers (calbindin 2, UCH-L1 and visinin-like protein 1), astroglial markers (S100B and GFAP), neurodegenerative disease proteins (total tau, pTau231, PSEN1, amyloid-beta-42 and 14-3-3γ), inflammatory cytokines (IL16, CCL2 and ficolin 2) and cell signalling- (SFRP1), cell metabolism- (MDH1) and autophagy-related (sequestome 1) proteins. Acute plasma levels of UCH-L1, PSEN1, total tau and pTau231 were correlated with subacute lesion volume. Sequestome 1 was positively correlated with white matter fractional anisotropy, whereas CCL2 was inversely correlated. Neuronal, astroglial, tau and neurodegenerative proteins were correlated with each other, IL16, MDH1 and sequestome 1. Exploratory clustering (k means) by acute protein expression identified three TBI subgroups that differed in injury patterns, but not in age or outcome. One TBI cluster had significantly lower white matter fractional anisotropy than control-predominant clusters but had significantly lower lesion subacute lesion volumes than another TBI cluster. Proteins that overlapped on two platforms had excellent (r > 0.8) correlations between values. We identified TBI-specific changes in acute plasma levels of proteins involved in neurodegenerative disease, inflammatory and cellular processes. These changes were related to patterns of injury, thus demonstrating that processes previously studied only in animal models are also relevant in human TBI pathophysiology. Our study highlights how proteomic approaches might improve classification and understanding of TBI pathophysiology, with implications for prognostication and treatment development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Brain Sciences, Imperial College London, London W12 0BZ, UK.
- UK Dementia Research Institute Centre for Care Research & Technology, Imperial College London and University of Surrey, London W12 0BZ, UK.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
- UK Dementia Research Institute, UCL, London W1T 7NF, UK.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg 431 41, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 413 45, Sweden.
ORCID-Profile: Henrik Zetterberg, Neil Graham, Thomas Parker, Federico Moro, David J Loane
Förderung
- ERA-NET NEURON Cofund
- The UK Dementia Research Institute
- NIHR
- Academy of Medical Sciences
- Swedish Research Council
- European Union's Horizon Europe research and innovation programme
- Alzheimer Drug Discovery Foundation
- AD Strategic Fund
Zitieren
APA
Li, L. M., Kodosaki, E., Heslegrave, A., Zetterberg, H., Graham, N., Zimmerman, K., Soreq, E., Parker, T., Garbero, E., Moro, F., Magnoni, S., Bertolini, G., Loane, D. J., & Sharp, D. J. (2025). High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury. Brain, 148(3), 1015-1030. https://doi.org/10.1093/brain/awae305
Vancouver
Li LM, Kodosaki E, Heslegrave A, Zetterberg H, Graham N, Zimmerman K, et al. High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury. Brain. 2025;148(3):1015-1030. doi:10.1093/brain/awae305
BibTeX
@article{Li2025,
author = {Li, Lucia M and Kodosaki, Eleftheria and Heslegrave, Amanda and Zetterberg, Henrik and Graham, Neil and Zimmerman, Karl and Soreq, Eyal and Parker, Thomas and Garbero, Elena and Moro, Federico and Magnoni, Sandra and Bertolini, Guido and Loane, David J and Sharp, David J},
title = {High-dimensional proteomic analysis for pathophysiological classification of traumatic brain injury},
journal = {Brain},
year = {2025},
volume = {148},
number = {3},
pages = {1015--1030},
doi = {10.1093/brain/awae305}
}
EUVIMED